Therefore, we hypothesized that MTL-CEBPA sensitizes AML cells to the FLT3 inhibitor, gilteritinib, by limiting leukemic cell proliferation and promoting myeloid differentiation. The gene discussed is FLT3; the disease is acute myeloid leukemia.